Cargando…

Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis

INTRODUCTION: Janus kinase (JAK) inhibitors are a class of targeted therapies for rheumatoid arthritis (RA) with established clinical efficacy. However, little is known about their efficacy compared with each other. This network meta-analysis (NMA) estimated the comparative efficacy of JAK inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pope, Janet, Sawant, Ruta, Tundia, Namita, Du, Ella X., Qi, Cynthia Z., Song, Yan, Tang, Patrick, Betts, Keith A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467453/ https://www.ncbi.nlm.nih.gov/pubmed/32297280 http://dx.doi.org/10.1007/s12325-020-01303-3

Ejemplares similares

Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2021)

A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
por: Edwards, Christopher J., et al.
Publicado: (2020)

Healthcare Costs of Not Achieving Remission in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study
por: Bergman, Martin, et al.
Publicado: (2021)

Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review
por: Ostor, Andrew J., et al.
Publicado: (2021)

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Emery, Paul, et al.
Publicado: (2018)

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2019)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2019)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2020)

Clinical use of Jak 1 inhibitors for rheumatoid arthritis
por: Nash, Peter
Publicado: (2021)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
por: Bergman, Martin, et al.
Publicado: (2021)

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis
por: Wang, Faping, et al.
Publicado: (2022)

Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Fakhouri, Walid, et al.
Publicado: (2021)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
por: Moura, Rita A., et al.
Publicado: (2021)

Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis
por: Zhang, Ning, et al.
Publicado: (2021)

Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE
por: Strand, Vibeke, et al.
Publicado: (2021)

Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
por: Pei, Heying, et al.
Publicado: (2018)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
por: Angelini, Jacopo, et al.
Publicado: (2020)

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
por: Harrington, Robert, et al.
Publicado: (2020)

Management of Fatigue in Rheumatoid Arthritis
por: Pope, Janet E
Publicado: (2020)

A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease
por: Tardella, Marika, et al.
Publicado: (2022)

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Robinson, Michael F., et al.
Publicado: (2020)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
por: Fragoulis, George E, et al.
Publicado: (2019)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Pulmonary nodules associated with JAK inhibitor therapy in rheumatoid arthritis: A case report
por: Pannell, N, et al.
Publicado: (2021)

Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis
por: Kaine, Jeffrey, et al.
Publicado: (2020)

A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2023)

Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?
por: Mehta, Puja, et al.
Publicado: (2020)

JAK/STAT pathway in pathology of rheumatoid arthritis (Review)
por: Ciobanu, Dana Alexandra, et al.
Publicado: (2020)

Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis
por: Jain, Divya, et al.
Publicado: (2019)

Early response to JAK inhibitors on central sensitization and pain catastrophizing in patients with active rheumatoid arthritis
por: Salaffi, Fausto, et al.
Publicado: (2022)

One of the active ingredients in Paeoniae Radix Alba functions as JAK1 inhibitor in rheumatoid arthritis
por: Xiao, Lu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vb63o8bkrhkrmig0ruhhj414pc